ATXI · Avenue Therapeutics, Inc. · Executive Compensation
$0.38
-0.05 (-10.71%)
At close · Mar 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, as described below, substantial doubt about the Company’s ability to continue as a going concern exists. These factors individually and collectively cause substantial doubt about the Company’s ability to continue as a going concern to exist within one year from the date of this report.”View the 10-Q filed Nov 6, 2026
Market Cap
$848,783
Shares
3.29M
Volume · Mar 19
173.84K
Avg daily vol (3M)
426.7K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Lucy Lu | Former Chief Executive Officer | $570,859 |
| Alexandra MacLean | Chief Executive Officer | $280,542 |
| Joseph Vazzano | Former Chief Financial Officer | $21,335 |
| David Jin | Interim Chief Financial Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Lucy Lu | Former Chief Executive Officer | $1,082,128 |
| Joseph Vazzano | Former Chief Financial Officer | $441,325 |
| David Jin | Interim Chief Financial Officer | — |
| Alexandra MacLean | Chief Executive Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Lucy Lu | Chief Executive Officer | $443,027 |
| Joseph Vazzano | Chief Financial Officer | $214,890 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Lucy Lu | Chief Executive Officer | $639,783 |
| Joseph Vazzano | Chief Financial Officer | $258,779 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Lucy Lu | Chief Executive Officer | $1,594,633 |
| Joseph Vazzano | Chief Financial Officer | $354,528 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Lindsay A. Rosenwald, M.D. | Director | Appointed | 2024-06-26 |
| Alexandra MacLean, M.D. | Director | Appointed | 2024-06-26 |
| Curtis Oltmans | Director |
Already on the board
Since at least 2021: re-election or new board role
|
2024-06-26 |
| Faith Charles | Director |
Already on the board
Since at least 2022: re-election or new board role
|
2024-06-26 |
| Neil Herskowitz | Director |
Already on the board
Since at least 2015: re-election or new board role
|
2024-06-26 |
| Jay Kranzler, M.D., Ph.D. | Director | Appointed | 2024-06-26 |
| Jay Kranzler, M.D., Ph.D. | Chairman of the Board | Appointed | 2023-03-08 |
| Alexandra MacLean, M.D. | director | Appointed | 2023-03-08 |
| E. Garrett Ingram | member of the Board and all committees thereof | Resigned | 2022-11-04 |
| Jaideep Gogtay | member of the Board and all committees thereof | Resigned | 2022-11-04 |
| Alexandra MacLean, M.D. | Chief Executive Officer | Appointed | 2022-08-03 |
Leadership
- Alexandra MacLean CEO, Board Member
- Alexandra MacLean, M.D. CEO, Board Member
- Jay Kranzler, M.D., Ph.D. Chairman, Board Member
- David Jin CFO
- Lucy Lu CFO
- Curtis Oltmans Board Member
- Faith Charles Board Member
- Faith L. Charles Board Member
- Jay Kranzler Board Member
- Lindsay A. Rosenwald Board Member
- Lindsay A. Rosenwald, M.D. Board Member
- Neil Herskowitz Board Member